acetylcarnitine has been researched along with Asymmetric Diabetic Proximal Motor Neuropathy in 26 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Animals with 4 weeks of hyperglycemia and reduced NCV treated with an aldose reductase inhibitor (sorbinil) or a short-chain acyl-carnitine (acetyl-L-carnitine [ALC]) daily for 16 weeks showed an improvement in NCV." | 3.69 | The effects of acetyl-L-carnitine and sorbinil on peripheral nerve structure, chemistry, and function in experimental diabetes. ( Carver, J; Korthals, JK; Lowitt, S; Malone, JI; Miranda, C; Salem, AF, 1996) |
| " LAC (or placebo) was started intramuscularly at a dosage of 1000 mg/day for 10 days and continued orally at a dosage of 2000 mg/day for the remainder of the study (355 days)." | 2.70 | Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. ( De Grandis, D; Minardi, C, 2002) |
| "Flurbiprofen treatment of ND rats replicated many of the biochemical and physiological abnormalities of EDN, i." | 1.31 | Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. ( Greene, DA; Larkin, D; Li, F; Marinescu, V; Pop-Busui, R; Stevens, MJ; Sullivan, K; Van Huysen, C, 2002) |
| "Sorbinil treatment was associated with normalized sciatic nerve sorbitol and myo-inositol; ALC treatment did not reduce the elevated sorbitol levels, but sciatic nerve myo-inositol content was no different from nondiabetic levels." | 1.29 | Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. ( Benford, S; Korthals, J; Lowitt, S; Malone, JI; Salem, AF, 1995) |
| "Treatment with sorbinil was associated with normalization of the tissue sorbitol (0." | 1.28 | Altered neuroexcitability in experimental diabetic neuropathy: effect of acetyl-L-carnitine. ( Corsico, N; Lowitt, S; Malone, JI; Orfalian, Z, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (50.00) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 5 (19.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sergi, G | 1 |
| Pizzato, S | 1 |
| Piovesan, F | 1 |
| Trevisan, C | 1 |
| Veronese, N | 1 |
| Manzato, E | 1 |
| Rolim, LC | 1 |
| da Silva, EM | 1 |
| Flumignan, RL | 1 |
| Abreu, MM | 1 |
| Dib, SA | 1 |
| Li, S | 1 |
| Chen, X | 1 |
| Li, Q | 2 |
| Du, J | 1 |
| Liu, Z | 1 |
| Peng, Y | 1 |
| Xu, M | 1 |
| Lei, M | 1 |
| Wang, C | 1 |
| Zheng, S | 1 |
| Zhang, X | 1 |
| Yu, H | 1 |
| Shi, J | 1 |
| Tao, S | 1 |
| Feng, P | 1 |
| Tian, H | 1 |
| Evans, JD | 1 |
| Jacobs, TF | 1 |
| Evans, EW | 1 |
| Kuritzky, L | 1 |
| Pop-Busui, R | 1 |
| Marinescu, V | 1 |
| Van Huysen, C | 1 |
| Li, F | 1 |
| Sullivan, K | 1 |
| Greene, DA | 3 |
| Larkin, D | 1 |
| Stevens, MJ | 3 |
| De Grandis, D | 1 |
| Minardi, C | 1 |
| Defani, MA | 1 |
| Zanoni, JN | 1 |
| Natali, MR | 1 |
| Bazotte, RB | 1 |
| de Miranda-Neto, MH | 1 |
| Sima, AA | 4 |
| Calvani, M | 1 |
| Mehra, M | 1 |
| Amato, A | 1 |
| Ohsawa, M | 1 |
| Miyata, S | 1 |
| Carlsson, A | 1 |
| Kamei, J | 1 |
| Quatraro, A | 1 |
| Roca, P | 1 |
| Donzella, C | 1 |
| Acampora, R | 1 |
| Marfella, R | 1 |
| Giugliano, D | 1 |
| Lowitt, S | 3 |
| Malone, JI | 3 |
| Salem, AF | 2 |
| Korthals, J | 1 |
| Benford, S | 1 |
| Ido, Y | 1 |
| McHowat, J | 1 |
| Chang, KC | 1 |
| Arrigoni-Martelli, E | 1 |
| Orfalian, Z | 2 |
| Kilo, C | 1 |
| Corr, PB | 1 |
| Williamson, JR | 1 |
| Ristic, H | 1 |
| Merry, A | 1 |
| Kamijo, M | 1 |
| Lattimer, SA | 2 |
| Feldman, EL | 1 |
| Helton, ED | 1 |
| Millington, DS | 1 |
| Miranda, C | 1 |
| Korthals, JK | 1 |
| Carver, J | 1 |
| Nakamura, J | 1 |
| Koh, N | 1 |
| Sakakibara, F | 1 |
| Hamada, Y | 1 |
| Hara, T | 1 |
| Sasaki, H | 1 |
| Chaya, S | 1 |
| Komori, T | 1 |
| Nakashima, E | 1 |
| Naruse, K | 1 |
| Kato, K | 1 |
| Takeuchi, N | 1 |
| Kasuya, Y | 1 |
| Hotta, N | 1 |
| Scarpini, E | 1 |
| Doneda, P | 1 |
| Pizzul, S | 1 |
| Chiodi, P | 1 |
| Ramacci, MT | 4 |
| Baron, P | 1 |
| Conti, G | 1 |
| Sacilotto, G | 1 |
| Arduini, A | 1 |
| Scarlato, G | 1 |
| Lo Giudice, P | 1 |
| Careddu, A | 1 |
| Magni, G | 1 |
| Quagliata, T | 1 |
| Pacifici, L | 2 |
| Carminati, P | 1 |
| Gorio, A | 3 |
| Di Giulio, AM | 2 |
| Tenconi, B | 1 |
| Donadoni, L | 1 |
| Germani, E | 1 |
| Bertelli, A | 2 |
| Mantegazza, P | 2 |
| Maccari, F | 2 |
| Ferraris, L | 1 |
| Bellucci, A | 1 |
| Piovesan, P | 1 |
| Corsico, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome; a Randomized Control Trial.[NCT02141035] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for acetylcarnitine and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
Effects of acetyl-L-carnitine in diabetic neuropathy and other geriatric disorders.
Topics: Acetylcarnitine; Aged; Alzheimer Disease; Analgesics; Diabetic Neuropathies; Humans; Mitochondria; P | 2018 |
Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy.
Topics: Acetylcarnitine; Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropa | 2019 |
Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy.
Topics: Acetylcarnitine; Diabetic Neuropathies; Humans; Vitamin B Complex | 2008 |
Acetyl-L-carnitine. Monograph.
Topics: Acetylcarnitine; Alcoholism; Alzheimer Disease; Attention Deficit Disorder with Hyperactivity; Cogni | 2010 |
Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data.
Topics: Acetylcarnitine; Animals; Diabetic Neuropathies; Humans; Nootropic Agents | 2007 |
4 trials available for acetylcarnitine and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial.
Topics: Acetylcarnitine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double | 2016 |
Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study.
Topics: Acetylcarnitine; Adolescent; Adult; Aged; Diabetic Neuropathies; Double-Blind Method; Female; Humans | 2002 |
Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials.
Topics: Acetylcarnitine; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Human | 2005 |
Acetyl-L-carnitine for symptomatic diabetic neuropathy.
Topics: Acetylcarnitine; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Female; Human | 1995 |
17 other studies available for acetylcarnitine and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
Managing diabetic peripheral neuropathic pain in primary care.
Topics: Acetylcarnitine; Analgesics; Antidepressive Agents; Diabetic Neuropathies; Drug Therapy, Combination | 2010 |
Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration.
Topics: Acetylcarnitine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase | 2002 |
Effect of acetyl-L-carnitine on VIP-ergic neurons in the jejunum submucous plexus of diabetic rats.
Topics: Acetylcarnitine; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Die | 2003 |
Preventive effect of acetyl-L-carnitine on the thermal hypoalgesia in streptozotocin-induced diabetic mice.
Topics: Acetylcarnitine; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Male; Mice; Mice, | 2008 |
Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes.
Topics: Acetylcarnitine; Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies | 1995 |
Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine.
Topics: Acetylcarnitine; Animals; Ca(2+) Mg(2+)-ATPase; Carnitine; Diabetes Mellitus, Experimental; Diabetic | 1994 |
Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat.
Topics: 6-Ketoprostaglandin F1 alpha; Acetylcarnitine; Alprostadil; Animals; Diabetic Neuropathies; Dinopros | 1996 |
Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K-ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat.
Topics: Acetylcarnitine; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dose-Response Rela | 1996 |
The effects of acetyl-L-carnitine and sorbinil on peripheral nerve structure, chemistry, and function in experimental diabetes.
Topics: Acetylcarnitine; Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies | 1996 |
Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats.
Topics: Acetylcarnitine; Aldehyde Reductase; Animals; Body Weight; Carnitine; Diabetes Mellitus, Experimenta | 1998 |
Acetyl-L-carnitine.
Topics: Acetylcarnitine; Alzheimer Disease; Animals; Depressive Disorder; Diabetic Neuropathies; HIV Infecti | 1999 |
L-carnitine and acetyl-L-carnitine in human nerves from normal and diabetic subjects.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Carnitine; Diabetic Neuropathies; Female; Humans; I | 1996 |
Autonomic neuropathy in streptozotocin diabetic rats: effect of acetyl-L-carnitine.
Topics: Acetylcarnitine; Animals; Autonomic Nervous System Diseases; Blood Glucose; Body Weight; Diabetes Me | 2002 |
Peptide alterations in autonomic diabetic neuropathy prevented by acetyl-L-carnitine.
Topics: Acetylcarnitine; Animals; Autonomic Nervous System Diseases; Diabetes Mellitus, Experimental; Diabet | 1992 |
Acetyl-L-carnitine prevents substance P loss in the sciatic nerve and lumbar spinal cord of diabetic animals.
Topics: Acetylcarnitine; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Lumbar Vertebrae; | 1992 |
Counteraction on experimentally induced diabetic neuropathy by levocarnitine acetyl.
Topics: Acetylcarnitine; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Male; Motor Activi | 1992 |
Altered neuroexcitability in experimental diabetic neuropathy: effect of acetyl-L-carnitine.
Topics: Acetylcarnitine; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Imidazoles; Imidaz | 1992 |